Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat, drug-resistant, gram-negative bacterial infections and viral infections, today announced leadership changes, as Tomas Heyman has been appointed to the Board of Directors as the newly created role of Non-Executive Chairman. In addition, Dr. Michael Diem has stepped down from the Board of Directors from his role as Independent Director after serving for six years.

“We are pleased to welcome Tom Heyman to our Board of Directors,” said Christopher J. Burns, President and Chief Executive Officer. “As a highly respected and seasoned executive and board member, Tom brings a diverse breadth of industry experience across multiple disciplines that will benefit Venatorx as we continue to progress our pipeline of novel anti-infective therapies. On behalf of the entire Company, I would like to personally thank Mike Diem for his unwavering commitment to Venatorx as an Independent Director on the Board for the past six years. We appreciate his contributions along with the endless support and guidance he has shared in helping the Company to achieve its mission.”

“I believe Venatorx is well positioned to address the growing global crisis of antibiotic multi-drug resistant infections,” said Heyman. “I’m very happy to join the Venatorx Board as Chairman as the Company continues to grow, achieve its scientific and regulatory milestones, and ultimately deliver new anti-infective therapies to patients in need.”